| Literature DB >> 21481793 |
Chunling Yi1, Scott Troutman, Daniela Fera, Anat Stemmer-Rachamimov, Jacqueline L Avila, Neepa Christian, Nathalie Luna Persson, Akihiko Shimono, David W Speicher, Ronen Marmorstein, Lars Holmgren, Joseph L Kissil.
Abstract
The Merlin/NF2 tumor suppressor restrains cell growth and tumorigenesis by controlling contact-dependent inhibition of proliferation. We have identified a tight-junction-associated protein complex comprising Merlin, Angiomotin, Patj, and Pals1. We demonstrate that Angiomotin functions downstream of Merlin and upstream of Rich1, a small GTPase Activating Protein, as a positive regulator of Rac1. Merlin, through competitive binding to Angiomotin, releases Rich1 from the Angiomotin-inhibitory complex, allowing Rich1 to inactivate Rac1, ultimately leading to attenuation of Rac1 and Ras-MAPK pathways. Patient-derived Merlin mutants show diminished binding capacities to Angiomotin and are unable to dissociate Rich1 from Angiomotin or inhibit MAPK signaling. Depletion of Angiomotin in Nf2(-/-) Schwann cells attenuates the Ras-MAPK signaling pathway, impedes cellular proliferation in vitro and tumorigenesis in vivo.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21481793 PMCID: PMC3075552 DOI: 10.1016/j.ccr.2011.02.017
Source DB: PubMed Journal: Cancer Cell ISSN: 1535-6108 Impact factor: 31.743